Key result
Endothelial insulin-like growth factor-1 (IGF-1) receptor deficiency significantly elevated atherosclerotic burden in apolipoprotein E-deficient mice by increasing endothelial permeability.
IGF-1 promotes endothelial barrier function, suggesting a potential therapeutic strategy for vascular diseases such as atherosclerosis.
No immediate clinical implications for atherosclerosis; leaves open whether IGF-1 receptor modulation affects human vascular disease.
Endothelial insulin-like growth factor-1 (IGF-1) receptor deficiency significantly elevated atherosclerotic burden in apolipoprotein E-deficient mice, mediated at least in part by downregulation of intercellular junction proteins and, thus, elevated endothelial permeability. This study revealed a novel role for IGF-1 in supporting endothelial barrier function. These findings suggest that IGF-1's ability to promote endothelial barrier function may offer a novel therapeutic strategy for vascular diseases such as atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Higashi et al. (2020) studied Atherosclerosis. Endothelial insulin-like growth factor-1 (IGF-1) receptor deficiency was evaluated on Atherosclerotic burden. Endothelial insulin-like growth factor-1 (IGF-1) receptor deficiency significantly elevated atherosclerotic burden in apolipoprotein E-deficient mice by increasing endothelial permeability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: